SHANSHAN (01749) issued a profit warning, expecting a net consolidated profit of about 3 million yuan for the first half of the year, a year-on-year decline.
Shanshan Holdings (01749) announced that it expects the Group to achieve a consolidated net profit of approximately RMB 3 million for the six months ending June 30, 2026, while it achieved a consolidated net profit of approximately RMB 12.1 million for the six months ending June 30, 2025.
SHANSHAN (01749) announced that it expects the Group to achieve a consolidated net profit of approximately RMB 3 million for the six months ending June 30, 2026, compared to a consolidated net profit of approximately RMB 12.1 million for the six months ending June 30, 2025.
The anticipated decline in net profit is primarily due to external factors continuously impacting terminal sales, such as industry-wide demand pressure, cautious consumer spending, and intensified offline homogeneous competition. Additionally, during the reporting period, the Group actively engaged in channel clearing and structural optimization, resulting in a temporary reduction in revenue scale, which led to a slight decline in gross profit and, consequently, an overall decrease in profit for the reporting period.
Related Articles

ORIENTAL EXPL (00430) issues a profit warning, expecting that integrated profit attributable to shareholders for the first half of the year will decrease to approximately HK$3 million to HK$3.2 million.

Jiangsu Hengrui Pharmaceuticals (01276): SHR-7590 injection has obtained the Drug Clinical Trial Approval Notification.

CHINA RES LAND (01109) reported a cumulative contract sales amount of approximately 130.6 billion yuan for the first seven months, an increase of 5.7% year-on-year.
ORIENTAL EXPL (00430) issues a profit warning, expecting that integrated profit attributable to shareholders for the first half of the year will decrease to approximately HK$3 million to HK$3.2 million.

Jiangsu Hengrui Pharmaceuticals (01276): SHR-7590 injection has obtained the Drug Clinical Trial Approval Notification.

CHINA RES LAND (01109) reported a cumulative contract sales amount of approximately 130.6 billion yuan for the first seven months, an increase of 5.7% year-on-year.

RECOMMEND





